Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Erlotinib versus docetaxel in advanced squamous non-small cell lung cancer stratified by VeriStrat
2012-001896-35Phase 3Completed
- Sponsor
- ETOP IBCSG Partners Foundation
- Start
- Jul 2012
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial in Pulmonary squamous cell carcinoma comparing Erlotinib with Docetaxel (2 arms). Primary endpoint: Progression-free survival. Started Jul 2012; status: completed.
02
Drugs
erlotinibdocetaxel
03
Conditions
Pulmonary squamous cell carcinoma
Beyond the preview
Go deeper on 2012-001896-35.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2012-001896-35.